Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Early treatment with a key drug to fight multiple sclerosis (MS) nearly halves the risk of progression to the full-blown disease, according to a study published online on Wednesday by The Lancet.
The treatment, glatiramer acetate, marketed as Copaxone, was tested in 16 countries among 481 patients with a telltale lesion in the central nervous system called clinically isolated syndrome.
The volunteers either received the drug or a dummy lookalike for up to three years.
Copaxone reduced the risk of developing "clinically definite" MS by 45 percent compared with a placebo.
In addition, the time it took for 25 percent of patients to develop the full-scale disease was more than doubled in the Copaxone group, at just under two years on average compared with just under one year in the placebo group.
Around a million people around the world are affected by MS, a degenerative disease in which the immune system attacks myeline, the fatty sheath that protects nerve fibres.
As a result, signals between nerve cells are delayed, disrupted or even blocked, rather like a poor connection in an electrical wire.
This causes worsening problems in coordination and balance, as well as blurred vision and slurred speech.
"This study establishes glatiramer acetate as an option for patients with clinically isolated syndrome who choose to start treatment early to improve control of the underlying disease process," says the new paper.
The study was led by Giancarlo Comi, a professor of neurology at Milan's Vita-Salute University in Italy.
Copaxone is currently approved for treating "relapsing-remitting" forms of MS.
ri/km/rom
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments